169 related articles for article (PubMed ID: 26731410)
1. A systematic review and mixed treatment comparison of monotherapy in early Parkinson's disease: implications for Latin America.
Márquez-Cruz M; Díaz-Martínez JP; Soto-Molina H; De Saráchaga AJ; Cervantes-Arriaga A; Llorens-Arenas R; Rodríguez-Violante M
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):97-102. PubMed ID: 26731410
[TBL] [Abstract][Full Text] [Related]
2. Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson's disease: a systematic review.
Jiang DQ; Wang HK; Wang Y; Li MX; Jiang LL; Wang Y
Neurol Sci; 2020 Jan; 41(1):101-109. PubMed ID: 31446579
[TBL] [Abstract][Full Text] [Related]
3. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.
Binde CD; Tvete IF; Gåsemyr J; Natvig B; Klemp M
Br J Clin Pharmacol; 2018 Sep; 84(9):1917-1927. PubMed ID: 29847694
[TBL] [Abstract][Full Text] [Related]
4. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
[TBL] [Abstract][Full Text] [Related]
5. Comparison of pramipexole and levodopa/benserazide combination therapy versus levodopa/benserazide monotherapy in the treatment of Parkinson's disease: a systematic review and meta-analysis.
Jiang DQ; Zang QM; Jiang LL; Wang Y; Li MX; Qiao JY
Naunyn Schmiedebergs Arch Pharmacol; 2021 Sep; 394(9):1893-1905. PubMed ID: 33959780
[TBL] [Abstract][Full Text] [Related]
6. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
7. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
9. Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.
Matsunaga S; Kishi T; Iwata N
J Alzheimers Dis; 2017; 56(4):1229-1239. PubMed ID: 28157097
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
Cereda E; Cilia R; Canesi M; Tesei S; Mariani CB; Zecchinelli AL; Pezzoli G
J Neurol; 2017 Jun; 264(6):1254-1263. PubMed ID: 28550482
[TBL] [Abstract][Full Text] [Related]
11. Comparison of selegiline and levodopa combination therapy versus levodopa monotherapy in the treatment of Parkinson's disease: a meta-analysis.
Jiang DQ; Li MX; Jiang LL; Chen XB; Zhou XW
Aging Clin Exp Res; 2020 May; 32(5):769-779. PubMed ID: 31175606
[TBL] [Abstract][Full Text] [Related]
12. The Efficacy and Safety of Piribedil Relative to Pramipexole for the Treatment of Early Parkinson Disease: A Systematic Literature Review and Network Meta-Analysis.
Chen X; Ren C; Li J; Wang S; Dron L; Harari O; Whittington C
Clin Neuropharmacol; 2020; 43(4):100-106. PubMed ID: 32658035
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
Marconi S; Zwingers T
Eur Rev Med Pharmacol Sci; 2014 Jul; 18(13):1879-82. PubMed ID: 25010617
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: A systematic review and meta-analysis.
Wang Y; Jiang DQ; Lu CS; Li MX; Jiang LL
Medicine (Baltimore); 2021 Nov; 100(44):e27511. PubMed ID: 34871213
[TBL] [Abstract][Full Text] [Related]
15. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Fahn S;
J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pramipexole extended-release in Parkinson's disease: a review based on meta-analysis of randomized controlled trials.
Shen T; Ye R; Zhang B
Eur J Neurol; 2017 Jun; 24(6):835-843. PubMed ID: 28480621
[TBL] [Abstract][Full Text] [Related]
17. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of rasagiline in addition to levodopa for the treatment of idiopathic Parkinson's disease: a meta-analysis of randomised controlled trials.
Cai JP; Chen WJ; Lin Y; Cai B; Wang N
Eur Neurol; 2015; 73(1-2):5-12. PubMed ID: 25358603
[TBL] [Abstract][Full Text] [Related]
19. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
Dooley M; Markham A
Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
[TBL] [Abstract][Full Text] [Related]
20. Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data.
Mínguez-Mínguez S; Solís-García Del Pozo J; Jordán J
Pharmacol Res; 2013 Aug; 74():78-86. PubMed ID: 23735235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
